News | March 31, 2021
Investment opportunities in India’s healthcare sector: NITI Aayog
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
The vaccine was 85 percent effective in preventing severe disease across all regions.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
